About Parthenon
Our Approach
We have assembled a truly cross-disciplinary team of world-class disease experts, clinicians, experienced drug hunters, mathematicians and engineers.
Our Drug Discovery Engine operates at the intersection of complex disease biology and explainable AI to deliver precision
therapeutics matched to the right patient population.
Our platform increases translational success of novel targets and co-targets to achieve new levels of efficiency in drug discovery cycle times, and bring medicines with curative potential to patients faster.
Our Team
Scientific Advisory Board
Doug Lauffenburger, PhD
Professor of Bio-Chemical Engineering
Massachusetts Institute of Technology
Joseph Paul Eder, MD
Professor of Medicine
(Medical Oncology)
Yale School of Medicine
Scott Hiebert, PhD
Professor of Biochemistry and Medicine,
Hortense B. Ingram Chair of
Cancer Research
Vanderbilt University
Avner Schlessinger, MD
Associate Professor of Medicine
Pharmacological Sciences
Icahn School of Medicine at Mt. Sinai
Michael Cecchini, MD
Assistant Professor of Medicine
(Medical Oncology)
Yale School of Medicine
Axel Parmentier, PhD
Associate Professor
Machine Learning
Ecole de Ponts | Paris
